Supernus Pharmaceuticals (SUPN) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to $19.0 million.
- Supernus Pharmaceuticals' Cost of Revenue rose 785.99% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.7 million, marking a year-over-year increase of 870.44%. This contributed to the annual value of $77.9 million for FY2024, which is 701.01% down from last year.
- Per Supernus Pharmaceuticals' latest filing, its Cost of Revenue stood at $19.0 million for Q3 2025, which was up 785.99% from $16.8 million recorded in Q2 2025.
- Supernus Pharmaceuticals' 5-year Cost of Revenue high stood at $26.1 million for Q4 2024, and its period low was $15.0 million during Q1 2021.
- Moreover, its 5-year median value for Cost of Revenue was $19.0 million (2025), whereas its average is $19.8 million.
- As far as peak fluctuations go, Supernus Pharmaceuticals' Cost of Revenue surged by 26016.38% in 2021, and later plummeted by 3048.17% in 2024.
- Supernus Pharmaceuticals' Cost of Revenue (Quarter) stood at $17.0 million in 2021, then surged by 35.07% to $23.0 million in 2022, then fell by 14.49% to $19.6 million in 2023, then soared by 32.97% to $26.1 million in 2024, then decreased by 27.33% to $19.0 million in 2025.
- Its Cost of Revenue stands at $19.0 million for Q3 2025, versus $16.8 million for Q2 2025 and $15.8 million for Q1 2025.